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Summary: We identified 92 adults with VZV encephalitis primarily affecting elderly or immuno-compromised 
patients. Diagnosis and treatment are often delayed and cerebral vasculitis not uncommon (16%). Risk factors 
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Background: Knowledge of the epidemiology and clinical characteristics of Varicella zoster virus 
(VZV) encephalitis remains limited.  
Methods: Nationwide prospective cohort study of adults treated for microbiologically confirmed 
VZV encephalitis at Danish departments of infectious diseases from 2015 to 2019. Modified Poisson 
regression analysis was used to compute adjusted relative risks (RR) of unfavorable outcome. 
Results: We identified 92 adults (49% female) with VZV encephalitis yielding an incidence of 
5.3/1,000,000/year (95% CI:4.2-6.6). The median age was 75 years (IQR 67-83) and immuno-
compromising conditions were frequent (39%). Predominant symptoms were confusion (76%), 
headache (56%), nausea (45%), gait disturbance (42%), and personality changes (41%). Cranial 
imaging showed cerebral vasculitis (including infarction and hemorrhage) in 14 (16%) patients and 
encephalitic abnormalities in 11 (13%) with predilection for the brainstem and deep brain structures. 
Intravenous acyclovir treatment was initiated a median of 13.4 hours (IQR 5.2-46.3) since admission, 
while cranial imaging and lumbar puncture were performed after 6.3 hours (IQR 2.5-31.0) and 18.5 
hours (IQR 4.9-42.0). In-hospital, 1-month, and 3-month mortalities were 4%, 9%, and 11%, 
respectively. Unfavorable outcome (Glasgow Outcome Score (GOS) of 1-4), was found in 69% at 
discharge, with age (adj. RR 1.02, 95% CI 1.01-1.03), vasculitis (adj. RR 1.38, 95% CI 1.02-1.86), 
and Glascow coma scale (GCS)<15 (adj. RR 1.32, 95% CI:1.01-1.73) identified as independent risk 
factors. 
Conclusion: VZV encephalitis occurs primarily in elderly or immuno-compromised patients with a 
higher incidence than previously estimated. The diagnosis is often delayed and risk factors for 
unfavorable outcome are age, cerebral vasculitis, and GCS<15. 
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Varicella zoster virus (VZV) is a frequent cause of sporadic viral encephalitis in the Western world 
and is associated with a mortality of 9-20% [1–3]. Incidence of VZV encephalitis has been 
estimated to be 2-4/1,000,000/year similar to that of herpes simplex virus encephalitis (HSE) [4–
6]. Primary infection with VZV presents as varicella (chickenpox), after which the virus establishes 
long-lasting latency in sensory cranial neurons or dorsal root ganglia [7]. Approximately 90 % of the 
adult world population is infected with VZV [8]. Reactivation of VZV can result in various clinical 
manifestations, of which the most frequent is herpes zoster.  Rarely, however, infected individuals 
may develop severe neurological complications, such as meningitis, encephalitis, cerebellitis or 
central nervous system (CNS) vasculitis. Risk factors for VZV encephalitis include age >50 years and 
immuno-compromising conditions such as AIDS, organ transplantation, cancer, or immune-
modulating therapy [9]. Moreover, a number of rare primary immunodeficiencies have also been 
associated with VZV encephalitis [10–12]. 
      The routine virologic analysis for VZV encephalitis is PCR analysis of cerebrospinal fluid 
(CSF)[2,13]. In addition, VZV CNS infection may be detected in the CSF by measuring intrathecal 
anti-VZV IgG, which may sometimes be positive late during infection and or in VZV vasculitis, 
where PCR may not always be positive [14]. Finally, brain magnetic resonance imaging (MRI) may 
show encephalitic changes, although there is no typical presentation and scans are often normal [15].  
      Previous studies of VZV encephalitis in adults are scarce and characterized by limited sample size 
[2,3,5] or restricted to laboratory surveillance without detailed clinical information [4]. Thus, further 
contemporary studies are essential in order to improve diagnosis and treatment. We used a nationwide 
prospective database on CNS infections to investigate the epidemiology, clinical characteristics, 
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Setting and study population 
We accessed the database of the Danish Study Group of Infections of the Brain (DASGIB) to identify 
all adults (≥18 years of age) treated for first-time VZV encephalitis at departments of infectious 
diseases (ID) in Denmark from 1
st
 of January 2015 to 30
th
 of September 2019 (Figure 1). DASGIB is 
a nationwide collaboration between all Danish departments of ID prospectively registering all patients 
with central nervous system (CNS) infections [16].  
Only patients with a confirmed microbiological diagnosis of VZV CNS infection (by positive PCR 
or intrathecal antibody ratio) were included. The diagnosis of VZV encephalitis was established by an 
infectious diseases specialist at each center according to criteria defined by the International 
Encephalitis Consortium (IEC) [17] or an altered mental status (i.e. impaired consciousness, lethargy, 
or personality changes) combined with other symptoms of encephalitis (e.g. fever or a focal 
neurological deficit). Cases of proven or suspected autoimmune encephalitis were excluded. Patient 
enrollment was evaluated by ad hoc case-to-case discussions at biannual study group meetings. 
Furthermore, database completeness was ensured through annual searches of International 
Classification of Diseases 10th revision codes (A88, B01.1, B02.1, G05) in local databases of all eight 
ID departments in Denmark. 
The entire Danish population has unrestricted access to tax-financed medical care. In accordance 
with recommendations of the Danish health authorities, all patients with CNS infections in Denmark 
are treated at specialized departments of ID. The adult (≥18 years of age) population of Denmark was 
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Baseline characteristics including demographics, time and place of admission, exposures, co-
morbidities, as well as clinical signs and symptoms at admission were prospectively collected in the 
database. During hospitalization we registered antiviral treatment, cranial imaging and laboratory 
results from the diagnostic workup. Timing of lumbar puncture and cranial imaging was extracted 
from electronic records at departments of biochemistry or radiology, respectively. Timing of antiviral 
therapy was identified in the electronic medication systems. Time to lumbar puncture, cranial 
imaging, and onset of antiviral therapy was computed as time from admission to each of the above 
events. 
Outcome was categorized according to the Glasgow Outcome Scale (GOS): 1. Death; 2. 
Vegetative state; 3. Severe sequelae and dependency upon others in daily life; 4. Moderate sequelae 
but with the ability to live independently; and 5. No or only mild sequelae [18]. Outcome was 
assessed at discharge and at outpatient visits one and three months after discharge. A GOS score of ≤4 
was considered an unfavorable outcome. 
 
Statistical analyses 
To describe baseline demographics, we used frequency distributions. Continuous non-parametric data 
were summarized using medians, interquartile ranges (IQR), and ranges. The 95% confidence 
intervals (CI) were estimated assuming binomial proportions. Categorical variables were compared by 
Chi squared test and continuous variables by Mann-Whitney U-test. A two-tailed significance level 
was set at P < 0.05. 
The incidence rate (IR) was calculated as the number of incident cases per million at risk based on 
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We used modified Poisson regression analysis [19] to compute relative risks (RR) with 95% CIs 
for unfavorable outcome at discharge adjusted for age, sex, cerebral vasculitis, time to IV acyclovir 
treatment (0-24 h, 24-48 h, and >48 h), GCS <15, and adjunctive dexamethasone treatment.  




The DASGIB cohort study was approved by The Danish Data Protection Agency (record no. 2012-
58-0018) and The Danish Board of Health (record no. 3-3013-2579/1 and 3-3013-3168/1). The study 
has been reported according to STROBE guidelines. 
 
Results 
During the study period, we identified 92 (26%) adults with VZV encephalitis out of 353 patients with 
encephalitis in the DASGIB database (Figure 1). We estimated an IR of 5.3/1,000,000/year (95% CI 
4.2-6.6).  
 
Patient characteristics  
All patients fulfilled the IEC major criterion of an altered mental status lasting ≥24 h at admission 
(87/92) or later during hospitalization (5/92), and 71/92 (77%) had confirmed encephalitis according 
to the IEC criteria. The remaining patients had an altered mental status combined with either CSF 
leukocytes >5/mL (n=15), temperature ≥38℃ (n=2), EEG suggestive of encephalitis (n=1), or were 
included due to hallucinations and personality changes combined with cutaneous zoster (n=3). 
Patients with VZV encephalitis had a median age of 75 years (IQR: 67-83) and 45/92 (49%) were 
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admission. Immuno-compromising conditions were present in 36/92 (39%) patients including 
immune-suppressive treatments such as prednisolone or other drugs (18), diabetes mellitus (11), solid 
or hematological cancer (10), and alcohol abuse (5). No patients had a known primary 
immunodeficiency. 
The median duration of symptoms before admission was 4 days (IQR: 2-7) and most patients 
presented with confusion (76%), headache (56%), nausea (45%), or a previous history of herpes 
zoster (70%). Other frequent clinical manifestations included gait disturbances (42%), personality 
changes (41%), and aphasia (21%). Notably, 38% of patients had a GCS <15. Only eight (9%) and 
seven (8%) patients had a GCS 12 and 10.  Median temperature at admission was 37.5C (IQR: 
36.8-38.3). We found no differences in the clinical presentation of VZV encephalitis with or without 
cutaneous herpes zoster besides rash. A tentative diagnosis of encephalitis was made in nine patients 
(11%) at admission, while the presence of herpes zoster was noted in another nine (11%). Other 
admission diagnoses were heterogeneous ranging from non-infectious neurological disorders (21%) to 
cerebrovascular disease (15%). 
 
Diagnostic workup  
Patients with VZV encephalitis had a median C-reactive protein of 6 mg/L (IQR: 3-23) and a median 
white blood cell (WBC) count of 7.710
9
/L (IQR: 6.1-9.1) (Table 2). Median time from admission to 
lumbar puncture was 18.5h (IQR: 4.9-42.0) and 82/91 (90%) had CSF pleocytosis (median WBC of 
14610
9 
cells/L [IQR; 50-286]) with a mononuclear predominance. VZV in the CSF was detected by 
PCR in  86/92 (93%) and by a positive intrathecal VZV-IgG index in 6/92 (7%). Among patients 
diagnosed by intrathecal VZV-IgG index, two patients had delayed lumbar puncture (>5 days after 
admission) and none had vasculitis. Of eight patients examined for autoimmune encephalitis 
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Cranial imaging was performed in 85/92 patients (92%, Table 3) with a median time from 
admission to first scan (CT or MRI) of 6.3h (IQR: 2.5-31). The most frequent pathologies included 
signs of vasculitis including infarction/hemorrhage (16%) and encephalitic changes (13%). We 
observed a clear predilection of abnormalities for the brainstem, deep brain structures including the 
basal ganglia, and the cerebellum. Vasculitis was detected a median seven days upon start of 
admission (IQR: 4-10). Notably, most patients did not show any radiological signs of intracranial 
pathology excluding age-related findings (e.g. leukoaraiosis/atrophy). Electroencephalography 
suggested encephalitis in 24/46 (52%). 
 
Treatment and outcome 
All patients were treated with intravenous (IV) acyclovir 10 mg/kg t.i.d. with a median time from 
admission to acyclovir administration of 13.4h (IQR: 5.2-46.3) (Table 4). In addition, 23/89 (26%) 
were initially treated with short courses of adjunctive dexamethasone (<96h) due to suspected 
bacterial meningitis until VZV encephalitis was confirmed. Vasculitis patients received longer 
courses of glucocorticoid. The median duration of IV acyclovir was 14 days (IQR: 7-14) followed by 
oral acyclovir in 43/90 (48%) for a median of 11 days (IQR: 7-15). Admission to the intensive care 
unit occurred in 13/92 (14%) of patients. 
      We observed in-hospital, 1- and 3-months mortality rates of 4/92 (4%), 8/92 (9%) and 10/92 
(11%), respectively, with all fatalities restricted to patients 75 years of age. Causes of death during 
admission were aspiration pneumonia and pontine hemorrhage. Unfavorable outcome (GOS<5) at one 
and three months after discharge occurred in 46/83 (55%) and 41/80 (51%) of patients. The presence 
of pre-existing physical or cognitive deficits were significantly associated with unfavorable outcome 
and 1-month mortality. Using modified Poisson regression, we identified age (adj. RR 1.02, 95% CI: 
1.01-1.03), vasculitis (adj. RR 1.38, 95% CI: 1.02-1.86), and GCS<15 (adj. RR 1.32, 95% CI: 1.01-
1.73) as independent risk factors for unfavorable outcome in VZV encephalitis in adjusted analyses. 
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The epidemiology, clinical characteristics and outcome of VZV encephalitis remain poorly described. 
In this prospective nationwide cohort study, we investigated the epidemiology and clinical 
presentation of VZV encephalitis in adult patients in Denmark considering incidence, clinical 
manifestations, diagnostic workup, time to treatment, and outcome. Our main findings included a 
higher incidence of VZV encephalitis than previously reported both in terms of general population 
incidence (5.3/1,000,000/year) [4,5] and proportion among encephalitis patients (26%) compared with 
other studies outside of Northern Europe [2,3,20]. The majority of patients were elderly and more 
than one third were immunocompromised. Signs of cerebral vasculitis were present in 16% and were 
detected a median seven days after time of admission. VZV vasculitis is most probably 
underdiagnosed with few patients having MRI angiography done, and vasculitis was independently 
associated with unfavorable outcome. Age and GCS<15 on admission were also associated with poor 
outcome. Finally, we identified significant delays in diagnosis and antiviral treatment initiation, which 
may have clinical implications. 
We estimated an IR in adults of 5.3/1,000,000/year, suggesting that VZV encephalitis and 
infectious encephalitis in general may be underreported [21]. The clinical phenotype of viral CNS 
infections often varies greatly ranging from relatively benign meningitis to severe encephalitis with 
neurological sequelae [1,22]. Thus, the differentiation between viral meningitis, meningoencephalitis, 
and encephalitis can be challenging, which could imply an overestimation of the IR. However, we 
applied the IEC major diagnostic criteria (altered mental status) combined with detection of VZV in 
the CSF of all patients to ensure strict enrollment and minimize this bias[17]. On the other hand, strict 
inclusion requiring a lumbar puncture could result in cases of VZV (meningo)encephalitis not being 
properly examined and referred to ID departments as required for inclusion in the cohort. Likewise, a 
few patients with VZV encephalitis occurring during chemotherapy/immunomodulatory treatment 
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The fraction of immunocompromised versus immunocompetent individuals acquiring VZV 
encephalitis remains unknown. Historically, VZV CNS infections have been described to mostly 
affect immunocompromised patients [9]. As VZV is increasingly recognized as a cause of CNS 
infection [1], the question remaining is whether VZV encephalitis should continue to be considered as 
a disease mostly restricted to immunocompromised patients. In our cohort, 39% of the patients were 
classified as immunocompromised, and many patients were elderly and subject to immunosenescence. 
This may imply future increases in VZV encephalitis given the increasing number of 
immunocompromised individuals and changing demographics towards a larger proportion of elderly 
persons. Still, the majority of patients in this study were not immunocompromised 
 We made several interesting observations requiring further elaboration. A high positive rate was 
encountered for the detection of VZV by PCR in CSF (86/92, 93%) which confirms this method as 
first choice. In contrast, only 6 (7%) individuals were diagnosed by intrathecal anti -VZV IgG titer 
suggesting that this analysis should be reserved for cases of putative false negatives from PCR 
analyses with a persistent clinical suspicion of VZV CNS infection. Radiological examinations 
showed that 14 (16%) patients had findings of cerebral vasculitis, thus constituting the most common 
intracranial pathology in our cohort followed by encephalitic changes in 11 (13%). Consistent with 
previous studies on VZV encephalitis, these radiological abnormalities were common in the 
brainstem, deep brain structures, and cerebellum [9,20,22,23]. Notably, we identified vasculitis as a 
risk factor for unfavorable outcome and this group of patients warrants further investigation. 
Adjunctive treatment of VZV encephalitis remains incompletely determined, particularly the 
question relating to the effect of glucocorticoids in limiting neuroinflammation. In herpes simplex 
encephalitis patients, adjunctive therapy with glucocorticoids has been reported an independent 
predictor of improved outcome [24], but robust evidence to support this clinical practice is still 
lacking [25]. Although 26% of the patients in the present study had received treatment with 
dexamethasone, we failed to find any significant associations to any outcome measures. This analysis 
is also likely to be confounded by indication, e.g. patients with more critical disease more likely to 
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should be considered in the treatment of VZV vasculitis [26]. Yet, a randomized controlled trial of 
glucocorticoids in VZV encephalitis is required to definitively answer this question. 
 An important finding of our study was that many patients were not suspected of VZV 
encephalitis at admission and the associated median delay in antiviral treatment of 13.4h after 
admission[27]. This could potentially aggravate the prognosis, however, we were unable to 
confirm this in our study. Focus on the importance the diverse clinical presentation of viral 
encephalitis and early administration of acyclovir should be emphasized. 
 In this cohort we found an unfavorable outcome (GOS <5) one month after discharge in 55% of the 
patients, which is higher than previously reported [3]. Ten (11%) patients died following the diagnosis 
of VZV encephalitis during admission until 3 months after discharge, all aged 75 years, and age was 
confirmed as an independent risk factor for unfavorable outcome together with presence of vasculitis 
and GCS<15 at admission. Knowledge on neurological sequelae of VZV encephalitis is still scarce 
and predominantly based on small descriptive case series [22,28,29]. Larger studies addressing the 
outcome of encephalitis in general do exist, though only with limited number of VZV patients. In one 
of these studies the mortality and risk of neurological sequelae in VZV encephalitis was equal to that 
of HSE [2,30]. The neurological sequelae varied from minor to severe and was mainly described as 
neuropsychological including impaired concentration and memory, slowing of cognitive processing 
and behavioral changes [22,28–30]. Unfortunately, limitations on detailed information regarding 
sequelae following discharge precluded further analyses of this in our cohort. 
The nationwide and population-based setting of this cohort study including patients from all ID 
departments in Denmark constitutes the key strengths of this study. Continuous data registration in a 
pre-defined registration form helped preventing potential recall bias or misclassification and allowed 
us to collect data independently of future events, such as death. Additionally, the use of DNA-based 
diagnostic technologies did not change during the four years of inclusion. Still, some limitations have 
to be considered when interpreting our results. Minor incidents of viral CNS infection could 
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However, according to the Danish Health Authorities all patients with CNS infections are to be 
treated by ID departments in Denmark and thus, we find this unlikely. Second, despite the prospective 
design of the study, data completeness for some variables varied. Some patients were transferred to 
the ID department late in their disease course, which may have caused limitations in data availability. 
Standardized outcome measurements in encephalitis are lacking and although GOS is frequently used 
in studies of CNS infections, it may have limited sensitivity in differentiating patients with moderate 
or minor sequelae (‘ceiling effect’) compared with the extended GOS score [31] Finally, the clinical 
follow-up of up to three months was not complete for all patients and some may experience further 
improvement for up to one year after infection. 
In conclusion, the incidence of VZV encephalitis among adults in Denmark is higher than 
previously reported and immuno-compromise is a frequent predisposing condition. Diagnosis remains 
difficult and treatment is often delayed. Radiological abnormalities included vasculitis and 
encephalitic lesions with predilection for brainstem, basal ganglia and cerebellum. We identified age, 
vasculitis and GCS<15 as independent risk factors for unfavorable outcome. Large prospective studies 
and randomized controlled trials are needed to increase knowledge on disease pathogenesis and 
prognostic factors in order to improve diagnosis and treatment of patients with VZV infection in the 
CNS. 
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Table 1. Baseline characteristics at admission of 92 adult VZV encephalitis patients in Denmark from 
2015-2019. 
Variable Obs N (%) / median (IQR) 
Age, years 92 75 (67-83) 
Sex, female  92 45 (49) 




Hematological cancer  
Diabetes mellitus  
HIV 
Prednisolone (any dosage) 
Other immuno-suppressants* 
Known primary immunodeficiency 























History of herpes zoster at any time before admission 83 58 (70) 












Median GCS at admission 
Fever (38.0C) 
Median temp. at admission (C) 
Aphasia 
Extremity motor/sensory deficits 
Cranial nerve palsy 
Seizures (preceding or at admission) 
Ataxia 
Diagnosis at admission 
       Non-infectious neurological disease 
       Cerebrovascular disease** 
       Non-CNS infection 
       Encephalitis 
       Herpes zoster 
       Psychiatric disease        

















































*Methotrexate, n=6; TNF-alpha inhibitor, n=1; azathioprin, n=1. **Includes stroke, cranial hemorrhages, and 
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Table 2. Biochemical and microbiological analyses of 92 adult VZV encephalitis patients in Denmark 
from 2015-2019. 




























Cerebrospinal fluid analysis 











CSF glucose (mM)  
Lactate (mM) 
CSF bacterial culture, positive 
Autoimmune encephalitis antibodies**, positive 
VZV encephalitis diagnosed by 
     PCR in CSF 
















146 (50-286; 1-1413) 
3 (1-7; 0-98) 
0.92 (0.7-1.5; 0.2-10.1) 
4 (0-300; 0-11,000 
3.5 (3.0-4.3; 1.6-8.3) 














CSF: Cerebrospinal fluid. CT: Computed tomography. EEG: Electroencephalography. MRI: Magnetic 
resonance imaging. PMN: Polymorphonuclear. WBC: White blood cell count. 
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Table 3. Results of cranial imaging and EEG in 92 adult VZV encephalitis patients in Denmark from 
2015-2019. 
Variable Obs N (%) / median (IQR) 
Cranial imaging (any) during admission 92 85 (92) 
Cranial CT scan 
Cranial MRI 
Both CT and MRI 
 72 (78) 
66 (72) 
53 (48) 
Time to cranial imaging (from time of admission) 





   Time to MRI scan (h) 66 71.3 (47.2-144) 
   Time to first cranial scan (h) 85 6.3 (2.5-31.0) 
Imaging findings 85  
   Vasculitis incl. brain infarction and hemorrhage*  14 (16) 
      Frontal lobe  3 
      Parietal lobe  4 
      Temporal lobe  1 
      Occipital lobe  2 
      Cerebellum  1 
      Brainstem  3 
      Other deep structures incl. basal ganglia  3 
   Encephalitic abnormalities*  11 (13) 
      Frontal lobe  1 
      Parietal lobe  1 
      Temporal lobe  1 
      Occipital lobe  - 
      Cerebellum  1 
      Brainstem  3 
      Other deep structures incl. basal ganglia  5 
   Generalized edema  1 (1) 
   Hydrocephalus  1 (1) 
   CNS malignancy  1 (1) 
   Other**  3 (4) 
EEG performed 87 46 (53) 
   EEG findings suggestive of encephalitis 46 24 (52) 
CT: Computed tomography. EEG: Electroencephalography. IQR: Interquartile ranges. MRI: Magnetic 
resonance imaging. *Several lesions were present in some patients. All brain infarctions occurred within eight 
days except for one which was diagnosed 74 days after admission. **Concomitant lesions suggestive of 
toxoplasmosis in one patient (HIV positive), basilar aneurysm in one patient not considered VZV vasculitis, and 
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Table 4. Treatment and outcome of 92 adult VZV encephalitis patients in Denmark from 2015-2019. 
Summary of treatment and outcome    
Variable Obs N (%) / median (IQR) 
Treatment 
Intravenous acyclovir 
Time to acyclovir administration (h)* 
      Duration of IV treatment (days) 
Oral acyclovir/valacyclovir after IV treatment 























Unfavorable outcome at discharge 
Unfavorable outcome one month since discharge 
















Pre-existing comorbidity and outcome 
 
  











Unfavorable outcome (GOS 1-4) 
At discharge 
1-month since discharge 

































Risk factors for unfavorable outcome (GOS 1-4) 
at discharge 
 














































GOS: Glascow Outcome Scale. ICU: Intensive care unit. IV: Intravenous. GCS: Glasgow coma scale. 
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Figure 1. The eight departments of infectious diseases in Denmark and the 
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